Atrial fibrillation and anticoagulation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) significantly elevates ischemic stroke risk via left atrial thrombus formation.
• Anticoagulant therapy, primarily warfarin, reduces embolic events but increases bleeding, especially in the elderly, leading to underuse.
• Aspirin's efficacy in lone AF is less certain, potentially suitable for younger patients with low embolic risk.

Purpose of the Study:

• To review current anticoagulant strategies for stroke prevention in atrial fibrillation.
• To compare the efficacy and safety of various anticoagulant options.
• To emphasize individualized treatment decisions based on benefit-risk assessment.

Main Methods:

• Review of existing literature on anticoagulant therapies for atrial fibrillation.
• Comparison of warfarin, aspirin, and newer agents like ximelagatran.
• Consideration of urgent cardioversion protocols.

Main Results:

• Warfarin effectively reduces stroke risk but carries a bleeding risk.
• Low-dose aspirin may be an option for select patients, but combination with warfarin is contraindicated.
• Ximelagatran shows promise as an effective alternative to warfarin with a better bleeding profile.
• Intravenous unfractionated heparin is standard for urgent cardioversion; LMWH with TEE is an alternative approach.

Conclusions:

• Treatment decisions for AF patients must be individualized based on a careful benefit-risk ratio.
• Emerging anticoagulants like ximelagatran may offer improved safety profiles.
• Optimizing anticoagulant use in AF remains crucial for stroke prevention.